@article{94f51df7409e40fa9b38be56355c5284,
title = "Safety and Pharmacokinetics of Casirivimab and Imdevimab (CAS + IMD) in Pediatric Outpatients With COVID-19",
abstract = "The safety of casirivimab + imdevimab (CAS + IMD) (anti-severe acute respiratory syndrome coronavirus 2 [SARS-CoV-2] monoclonal antibodies [mAbs]) in pediatric outpatients with coronavirus disease 2019 (COVID-19) was evaluated in a randomized phase 1/2/3 trial. Consistent with adults, CAS + IMD was generally well tolerated with low drug-induced immunogenicity rates. The findings support the development of next-generation anti-SARS-CoV-2 mAbs for at-risk pediatric patients.",
keywords = "COVID-19, monoclonal antibodies, outpatients, pediatrics, treatment",
author = "Norton, {Thomas D.} and Mazhar Thakur and Samit Ganguly and Shazia Ali and Jesse Chao and Alpana Waldron and Jing Xiao and Turner, {Kenneth C.} and Davis, {John D.} and Irvin, {Susan C.} and Cynthia Pan and Dominique Atmodjo and Hooper, {Andrea T.} and Hamilton, {Jennifer D.} and Mohamed Hussein and Danise Subramaniam and Lilia Roque-Guerrero and Anita Kohli and Eleftherios Mylonakis and Geba, {Gregory P.} and Edward Cox and Ned Braunstein and Paula Dakin and Bari Kowal and Rafia Bhore and DiCioccio, {A. Thomas} and Diana Hughes and Herman, {Gary A.}",
note = "Publisher Copyright: {\textcopyright} The Author(s) 2024.",
year = "2024",
month = nov,
day = "1",
doi = "10.1093/jpids/piae105",
language = "English (US)",
volume = "13",
pages = "589--593",
journal = "Journal of the Pediatric Infectious Diseases Society",
issn = "2048-7193",
publisher = "Oxford University Press",
number = "11",
}